Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.…
Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026
Actuate Therapeutics, Inc. Common stock (NASDAQ: ACTU) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 0.2253 USD on 20 November 2026, down 96.2% over 52 weeks. Its 52-week range is 0.1741 USD to 7.900 USD: the price is 97.1% below the high and 29.4% above the low.
Its market capitalisation is 13.60M USD.
Actuate Therapeutics, Inc. Common stock reports return on equity of -280.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 4.43M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 March 2027.